In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Japan Pharma Lobbies Likely to Retain Chiefs as Off-Year Re-Pricing Debate Looms
February 21, 2020
-
BUSINESS Takeda Vaults to 9th in Global Pharma Ranking after Shire Buy, Roche Tops List: Jiho Tally
February 21, 2020
-
BUSINESS GSK Japan Resurrects “Sales” for Rep Performance Review, Doctor Payments; Critics Say It’s a Rollback
February 20, 2020
-
BUSINESS Japan Pharma Market Logs 1st Growth in 3 Years in 2019, Keytruda Is the Best-Seller: IQVIA
February 19, 2020
-
REGULATORY Authorized Generics for Memary, Celecox among Approval List towards June Listing
February 18, 2020
-
REGULATORY MHLW Panel to Review Nippon Shinyaku’s Oligonucleotide DMD Drug, Latuda and More on Feb. 28
February 18, 2020
-
REGULATORY Zolgensma Up for Japan Advisory Panel Meeting on Feb. 26, Listing Expected as Early as May
February 17, 2020
-
BUSINESS Eisai Pulls Belviq from US Market after FDA Flags Cancer Risks
February 17, 2020
-
REGULATORY MHLW to Weigh All-Year Invitation for Sakigake Requests: Top Pharmacy Officer
February 14, 2020
-
BUSINESS Ono Revamps Japan Sales Structure to Gear Up for New Launches
February 13, 2020
-
REGULATORY MHLW Calls for Stable Supplies of HIV Drugs amid Coronavirus Outbreak
February 13, 2020
-
BUSINESS With 2 New Deals Inked, Meiji Hunkering Down for Full-Scale Entry into Hematology Market
February 12, 2020
-
ORGANIZATION FPMAJ Creates Scheme to Deal with Drug Supply Disruptions; Companies to Set Up “Supply Adjustment Teams”
February 12, 2020
-
INTERVIEW Improper Materials Apparently Decreased after Promotion Guidelines Introduced: Pharmacist
February 10, 2020
-
BUSINESS With Orix Deal, Reborn Kobayashi Kako Aims to Become Follow-Up to Big 3 Generic Players
February 7, 2020
-
ORGANIZATION RAD-AR Council Accelerating Initiative to Prepare Medication Guides in English toward Tokyo 2020 Olympic and Paralympic Games
February 6, 2020
-
ORGANIZATION Japan Red Cross Set to Push Formularies at All Group Hospitals, Despite Medical Fee Plan Dropped
February 5, 2020
-
BUSINESS Oncolys Hopes for Chugai’s Participation in US Development of Telomelysin: Chief
February 4, 2020
-
BUSINESS Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
February 3, 2020
-
BUSINESS Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan
January 31, 2020
ページ
The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…